Samsung Partners With Alcedis to Advance Clinical Research Using Wearable-Based Endpoints

Samsung Electronics has entered a partnership with Alcedis, a digital-first clinical research organization, to transform wearable-captured biometrics into meaningful evidence for clinical trials. The collaboration seeks to address the industry-wide challenge of translating continuous, real-world health signals into clinically validated data for pharmaceutical and research organizations. By integrating advanced biosensors with clinical expertise, the two companies aim to maximize efficiency in terms of both cost and time during the research lifecycle.

Samsung is leveraging its latest advancements in wearable technology, including the Galaxy Watch’s biosensors, to enable the continuous collection of physiological data from consenting participants. The platform incorporates clinically validated measurements such as bioelectrical impedance analysis (BIA) and electrodermal activity (EDA), alongside Software as a Medical Device (SaMD) features for detecting obstructive sleep apnea and Atrial Fibrillation. This integrated approach is designed to support biomarker development and digital endpoint innovation, providing researchers with fine-grained control over biosensors and access to device-level insights.

Under the collaboration, Alcedis will lead study execution and participant engagement, while Samsung provides the necessary wearable technology and research-related technical infrastructure. This partnership aims to bridge the gap between everyday health monitoring and scientific discovery, allowing for faster study setup and more robust evidence generation. According to Jongmin Choi, Head of Health R&D Group at Samsung’s Mobile eXperience Business, the collaboration is a step toward a more collaborative future in clinical research that brings together technology and scientific expertise to deepen the understanding of human health.

Hanno Härtlein, CEO of Alcedis, stated that the ability to capture meaningful health data outside of traditional clinical settings is vital for the future of the industry. The joint effort combines Samsung’s scalable infrastructure with Alcedis’s data-driven trial methodology to accelerate the development of patient-centric healthcare innovations. By providing a foundation for scientifically meaningful digital biomarkers, the partnership intends to help researchers gain real-world insights and accelerate innovation across the broader healthcare ecosystem.